Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (291-300 of 584) with videos related to

Pageof 59
Sort By:
Cancer|October 27, 2017
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapyHagop M Kantarjian, Carla M Mamolo, Carlo Gambacorti-Passerini, et al.
Blood|May 31, 2002
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosideElihu H Estey, Peter F Thall, Francis J Giles, et al.
The Pediatric Infectious Disease Journal|December 25, 2010
Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccineYadira Molto, Jennifer E Cortes, Lucia Helena De Oliveira, et al.
Haematologica|August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesGautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Journal of Materials Science. Materials in Medicine|May 10, 2012
In vitro and in vivo evaluation of the biocompatibility of a calcium phosphate/poly(lactic-co-glycolic acid) compositeA Gala-García, M B H Carneiro, G A B Silva, et al.
Cancer|August 12, 2003
Phase II study of alemtuzumab in chronic lymphoproliferative disordersAlessandra Ferrajoli, Susan M O'Brien, Jorge E Cortes, et al.
Haematologica|April 19, 2015
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapyGautam Borthakur, Herve Dombret, Philippe Schafhausen, et al.
Leukemia|December 22, 2015
Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trialsP D le Coutre, T P Hughes, F-X Mahon, et al.
Leukemia|February 4, 2016
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyZ Chen, J E Cortes, J L Jorgensen, et al.
Leukemia Research|October 21, 2021
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemiasVamsi Kota, Tim H Brümmendorf, Carlo Gambacorti-Passerini, et al.
Pageof 59

Showing results (291-300 of 584) with videos related to

Sort By:
Pageof 59
Cancer|October 27, 2017
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapyHagop M Kantarjian, Carla M Mamolo, Carlo Gambacorti-Passerini, et al.
Blood|May 31, 2002
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosideElihu H Estey, Peter F Thall, Francis J Giles, et al.
The Pediatric Infectious Disease Journal|December 25, 2010
Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccineYadira Molto, Jennifer E Cortes, Lucia Helena De Oliveira, et al.
Haematologica|August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesGautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Journal of Materials Science. Materials in Medicine|May 10, 2012
In vitro and in vivo evaluation of the biocompatibility of a calcium phosphate/poly(lactic-co-glycolic acid) compositeA Gala-García, M B H Carneiro, G A B Silva, et al.
Cancer|August 12, 2003
Phase II study of alemtuzumab in chronic lymphoproliferative disordersAlessandra Ferrajoli, Susan M O'Brien, Jorge E Cortes, et al.
Haematologica|April 19, 2015
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapyGautam Borthakur, Herve Dombret, Philippe Schafhausen, et al.
Leukemia|December 22, 2015
Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trialsP D le Coutre, T P Hughes, F-X Mahon, et al.
Leukemia|February 4, 2016
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyZ Chen, J E Cortes, J L Jorgensen, et al.
Leukemia Research|October 21, 2021
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemiasVamsi Kota, Tim H Brümmendorf, Carlo Gambacorti-Passerini, et al.
Pageof 59